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Abstract
Human leukocyte antigen-G (HLA-G) is known to be implicated in a tumor-driven immune escape mechanism in
malignancies. The purpose of this study was to investigate HLA-G polymorphism and expression in breast cancer. HLA-G
alleles were determined by direct DNA sequencing procedures from blood samples of 80 breast cancer patients and 80
healthy controls. Soluble HLA-G (sHLA-G) was measured by enzyme-linked immunosorbent assay (ELISA) from serum
specimens. HLA-G expression in breast cancer lesions was also analyzed by immunohistochemistry staining. The presence of
HLA-G 39 untranslated region (UTR) 14-bp sequence was analyzed and found to be associated with reduced risk of breast
cancer susceptibility based on HLA-G expression in tissues (P= 0.0407). Levels of sHLA-G were higher in the breast cancer
group (median 117.2 U/mL) compared to the control group (median 10.1 U/mL, P,0.001). The area under the receiver
operating characteristic curve (AU-ROC) values of sHLA-G for differentiating breast cancer from normal controls and for
detecting metastasis from other stages of breast cancer were 0.89 and 0.79, respectively. HLA-G polymorphism and
expression may be involved in breast carcinogenesis and sHLA-G concentrations could be used as a diagnostic marker for
detecting breast cancer.
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Introduction
Breast cancer is the most common cancer among women
worldwide; approximately 1.2 million cases of breast cancer are
diagnosed annually. Breast cancer is also the most frequent cause
of cancer-related mortality, accounting for almost 411,000 deaths
every year [1,2]. Although the overall incidence of breast cancer
has increased, early diagnosis and treatment through screening
have helped reduce the mortality from breast cancer [3].
Therefore, the investigation of appropriate tumor markers for
early detection and monitoring is necessary.
Human leukocyte antigen-G (HLA-G) belongs to the non-
classical HLA class I family of genes and is located at chromosome
6p21 [4]. The diversity of the promoter and the 39-untranslated
region (UTR) of the HLA-G gene controls the expression of HLA-
G protein [5]. The HLA-G gene encodes seven isoforms by
alternative splicing of primary transcripts, which include four
membrane-bound (HLA-G1, -G2, -G3, and -G4) and three
soluble isoforms (HLA-G5, -G6, and -G7) [6]. Aberrant HLA-G
expression has been closely associated with several pathological
conditions, including transplantation, autoimmune and inflamma-
tory diseases, viral infections, and malignancies [7]. HLA-G exerts
its function mainly against natural killer (NK) cells, T lymphocytes,
and antigen-presenting cells through binding to the inhibitory
receptors such as immunoglobulin-like transcripts (ILT)-2/CD85j,
ILT-4/CD85d, and killer cell immunoglobulin receptor (KIR)
2DL4/CD158d [8–10]. Furthermore, soluble HLA-G (sHLA-G) is
known to interact with CD8 co-receptor and induces the apoptosis
of NK and T cells [11]. Thus, increased expression of HLA-G can
lead to immune tolerance of the host. The tolerogenic properties
of HLA-G have beneficial effects in pregnancy, transplantation,
and inflammatory diseases by reducing immune reaction respons-
es, whereas they are deleterious in cancer and viral infections by
permitting escape of tumor or virus-infected cells from anti-tumor
or anti-viral responses, respectively [4].
The HLA-G alleles have relatively restricted polymorphism and
low sequence variations in different populations [12–16]. Forty-
seven alleles have been assigned to the HLA-G gene, primarily in
exons 2, 3, and 4. The HLA-G gene also has the presence or
absence of 14-base pair (bp) at the 39-UTR [14,17]. These HLA-G
polymorphisms have been associated with several types of
malignancies such as hepatocellular carcinoma, esophageal
cancer, transitional cell carcinoma of bladder, uterine cervical
cancer, and childhood neuroblastoma [18–22]. However, HLA-G
genotypes in breast cancer patients have not yet been widely
reported.
As one of the expressive forms of the HLA-G gene, sHLA-G
antigens are derived from the release of membrane-bound HLA-G
isoforms (HLA-G1s for HLA-G1 shedding) and from the secretion
of sHLA-G isoforms themselves (HLA-G5). sHLA-G could affect
anti-tumor immune reactions both locally at the tumor site and
systemically through the circulation [23]. Previous studies reported
that sHLA-G concentrations are significantly increased in patients
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with tumors such as cervical, colorectal, gastric, esophageal, and
lung cancer, as well as breast cancer [7,24,25].
HLA-G antigens in tissue can be observed directly by
immunohistochemistry. Several studies revealed that HLA-G
was more frequently observed in advanced stages of the disease
and tumor grade in breast cancer, [26,27] indicating its
considerable clinical relevance to breast cancer.
The aim of this study was to evaluate the diagnostic utility of
sHLA-G as a tumor marker in comparison to the conventionally
used cancer antigen (CA) 15-3 and carcinoembryonic antigen
(CEA) markers in breast cancer. In addition, the association
between HLA-G polymorphism and expression was analyzed in
the same patient population to investigate the possible mechanism
of HLA-G in breast carcinoma.
Materials and methods
1. Ethics statement
This study was approved by the independent Institutional
Review Board of Severance Hospital and informed consents were
written.
2.Study subjects
A total of 80 patients with breast cancer, who agreed to
participate in our study, signed the informed consent form and
received operations at our hospital, were randomly selected
between July 2012 and July 2013. The patients were confirmed
as having breast cancer based on pathological features of tissue
specimens. None of the patients received preoperative anti-cancer
treatment or had malignancies other than breast cancer.
Recurrent breast cancer cases were also excluded. Tumor staging
was stratified according to the sixth edition of the tumor-node-
metastasis (TNM) classification by the International Union Against
Cancer. Patient data including age, gender, histologic diagnosis,
tumor grade, and clinical stage were documented. Eighty healthy
controls were also selected among individuals who visited our
hospital for physical checkups and had no clinical evidence of
breast cancer or any other overt diseases. All assays were
performed to both breast cancer patients and normal controls
except immunohistochemistry. We could not obtain the breast
tissues of normal controls because the biopsies of normal controls
were rarely conducted and none of them agreed to provide their
normal breast tissues.
3. HLA-G allele assignment
HLA-G alleles were analyzed by nucleotide sequence variations
at exons 2, 3, 4, and 5. DNA was extracted from ethylenedi-
aminetetraacetic acid (EDTA)-blood samples with the QIAamp
DNA Mini Kit (Qiagen; Du¨sseldorf, Germany). The procedures
were automated by using QIAcube (Qiagen). The exon 2, 3, 4 and
5 were amplified using the following primer sequences: G_F
(TTCTCTCCTCCTTCTCCTAACC) in the 59UTR and G_R2
(TCACCCCTTCCTTACCTGAGC) in the intron 5. PCR was
performed under the following amplification conditions: 95uC for
5 minutes followed by 32 cycles of 97uC for 20 seconds, 64uC for
45 seconds, and 72uC for 150 seconds, and a final extension at
72uC for 5 minutes. The PCR products were then purified using
the Exonuclease I/Shrimp Alkaline Phosphatase mixture provided
by Biowithus Inc. (Seoul, Korea), by incubation at 37uC for 50
minutes and at 85uC for 15 minutes. The purified PCR product
was directly sequenced with the primers presented in the Table S2
and under the following conditions: 96uC for 30 seconds followed
by 25 cycles at 96uC for 10 seconds, 50uC for 5 seconds, and 60uC
for 4 minutes, and finalized at 10uC. The sequences were analyzed
using BIOWITHUS SBT Analyzer software and compared to the
reference sequences recognized by the World Health Organization
(WHO) and the international ImMunoGeneTics information
system (IMGT), based on exon polymorphisms. For the presence
of HLA-G 14-bp polymorphism analysis within the 39UTR of
HLA-G, the 39UTR of HLA-G was amplified by PCR and detected
by electrophoresis on 3% agarose gel. The primers used for the 14-
bp polymorphism analysis were GE14HLAG (GTGATGGG-
CTGTTTAAAGTGTCACC) and RHG4 (GGAAGGAATG-
CAGTTCAGCATGA) [13]. The deleted and inserted allele
generated a 210-bp and a 224-bp PCR fragment, respectively.
4. Immunohistochemistry for HLA-G antigens in tissue
Four micrometer-thick sections of the paraffin-embedded breast
tissue blocks were cut and mounted on polylysine-coated slides.
After deparaffinization, antigen retrieval was processed in 0.01 M
Trizma EDTA buffer (pH 9.0) using a microwave oven. Endog-
enous peroxidase was blocked for 10 minutes in a 3.0% hydrogen
peroxide solution at room temperature. Anti-HLA-G mAb (1:50;
Enzo Life Sciences International, Inc.; Butler Pike, PA, USA) was
added and incubated for one hour at room temperature, and
overnight at 4uC. The clone of monoclonal antibody was MEM-
G/1 and the antibody was designed to recognize the membrane
bound isoform HLA-G (human denatured HLA-G heavy chain).
After washing with 0.01 M phosphate-buffered saline (PBS)
solution, the binding sites of the primary antibody were visualized
through secondary antibody and di-amino benzidine solution
using a Dako EnVison kit (Dako; Glostrup, Denmark). Sections
were counterstained with hematoxylin, dehydrated, and mounted.
All of the slides were stained concurrently to avoid inter-assay
variation.
HLA-G immunoreactivity was determined in a binary manner
based on the percentage of HLA-G-positive tumor cells. The cut-
off value for determining positivity of HLA-G expression was 25%
of staining area, irrespective of staining intensity.
5. Assay for serum sHLA-G
Serum sHLA-G levels were measured using the Exbio/
BioVendor sHLA-G enzyme-linked immunosorbent assay
(ELISA) kit (Enzo Life Sciences International, Inc.; Butler Pike,
PA, USA). In the assay, calibrators and samples were incubated in
microplate wells coated with monoclonal anti-human sHLA-G
antibody. After incubation for 1 hour and washing procedures,
monoclonal anti-human b2-microglobulin antibody, labeled with
horseradish peroxidase (HRP), was added to the wells and
incubated for 1 hour. Following the washing process, the bound
HRP conjugate reacted with a substrate (tetramethylbenzidine),
and the reactions were read as optical densities (ODs) on an
automated ELISA plate reader. Finally, sHLA-G concentrations
(U/mL) in the samples were calculated using the calibration curve
constructed by plotting the ODs against concentrations of
calibrators provided by the manufacturer.
6. Determination of CA15-3 and CEA
CA15-3 levels were assayed by using the Vitros-3600 system
(Ortho-Clinical Diagnostics; Rochester, NY, USA) with Vitros
Immunodiagnostic Products CA15-3 (Ortho-Clinical Diagnostics).
Tests for CEA were performed using the UniCel DxI 800 Access
Immunoassay System with the CEA test kit (Beckman Coulter
Inc.; Brea, CA, USA). Each assay was performed according to the
respective manufacturer’s instructions based on chemiluminescent
reactions.
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7. Statistical analysis
Statistical analyses were performed using Analyse-it Method
Evaluation Edition version 2.22 software (Analyse-it Software Ltd.;
City West Business Park, Leeds, UK) and PASW version 18.0
(formerly SPSS statistics, SPSS Inc.; Chicago, IL, USA). Multiple
comparisons among continuous variables of the study groups were
performed using the Kruskal-Wallis test with pairwise comparison
and Bonferroni correction to compensate for alpha statistical
errors. Continuous variables were also compared between two
groups by using Mann-Whitney U tests, and categorical variables
of the study groups were assessed using chi-square tests. The
correlation between the levels of sHLA-G with CA15-3 and CEA
were analyzed by Spearman’s rank test. Receiver operating
characteristic (ROC) curve analysis was performed to evaluate
the diagnostic performances of sHLA-G, CA15-3, and CEA for
differentiating breast cancer (n = 80) from healthy control (n = 80)
samples. The AU-ROC of sHLA-G for breast cancer detection
was compared to those of CA15-3 and CEA. The Pearson chi-
square test was used to determine the association between HLA-G
expression and clinicopathological parameters in the immunohis-
tochemical studies. Binary logistic regression analysis was
performed with breast cancer as the dependent variable and the
HLA-G genotypes as co-variables to calculate odds ratios (ORs). P-
values less than 0.05 were considered statistically significant in all
analyses.
Results
1. Characteristics of the study groups
No significant difference was observed between the age of the
subjects in all groups, according to the TNM stages, except
between the control and overall breast cancer groups. The median
age for the breast cancer group was 52.0 years (1st to 3rd quartiles
= 47.0 to 62.2 years), while that of the control group was 44.5
years (1st to 3rd quartiles = 34.0 to 58.6 years). Only female
subjects were included in this study.
2. The association of HLA-G alleles and genotypes with
breast cancer
The distribution and ORs of the HLA-G alleles and genotypes
by disease status (with allele frequency of 5% or more) are
presented in Table 1. We covered the allele frequency more than
5% according to the criteria of a previous report by Ferguson et al.
[21]. In the study population, HLA-G *01:04:01 and G*01:01:01/
*01:04:01 were the most prevalent allele and genotype, respec-
tively. There was no HLA-G polymorphism found that was
significantly more frequent in patients with breast cancer than in
control subjects, and therefore, no polymorphism was associated
with the risk for breast cancer. The allele of the presence of HLA-G
39UTR 14-bp sequence was found less frequently in the breast
cancer group than in the control group (19.4 versus (vs.) 25.0%).
3. Concentration of sHLA-G according to
clinicopathological parameters and HLA-G genotypes
The clinicopathological characteristics of the breast cancer
group are shown in Table 2. Levels of sHLA-G were significantly
associated with metastasis and modified TNM stage (P,0.05).
Figure 1 also shows the serum concentrations of sHLA-G in the
control group and based on the stages of disease in the breast
cancer group. Levels of sHLA-G were significantly higher in
patients with breast cancer than in the control group (median
Table 1. Frequencies and odds ratios of HLA-G genotypes in breast cancer patients and control subjects.
Genotypes Control Breast cancer P-value1 OR 95% CI P-value2
N 80 (%) 80 (%)
Allele
G*01:01:01 54 (33.8) 59 (36.9) 0.3855 - - -
G*01:01:02 12 (7.5) 16 (10.0) 0.4053 1.22 0.53–2.81 0.6400
G*01:01:03 10 (6.3) 7 (4.4) 0.4415 0.64 0.23–1.80 0.3987
G*01:04:01 63 (39.4) 70 (43.8) 0.1395 1.02 0.621.68 0.9477
+14 bp 40 (25.0) 31 (19.4) 0.2260 0.72 0.42–1.23 0.2270
Genotype
G*01:01:01/*01:04:01 20 (25.0) 19 (23.8) 0.8539 - - -
G*01:04:01/*01:04:01 13 (16.3) 20 (25.0) 0.1714 1.62 0.63–4.14 0.3143
G*01:01:01/*01:01:01 8 (10.0) 15 (18.8) 0.1147 1.97 0.68–5.72 0.2101
G*01:01:01/*01:01:02 5 (6.3) 5 (6.3) 1.0000 1.05 0.26–4.22 0.9423
G*01:01:03/*01:04:01 5 (6.3) 4 (5.0) 0.7315 0.84 0.20–3.62 0.8172
G*01:01:01/*01:01:03 5 (6.3) 3 (3.8) 0.4682 0.63 0.13–3.02 0.5645
G*01:01:02/*01:04:01 3 (3.8) 5 (6.3) 0.4682 1.75 0.37–8.37 0.4809
214 bp/214 bp 44 (55.0) 54 (67.5) - - -
214 bp/+14 bp 32 (40.0) 21 (26.3) 0.0694 0.53 0.27–1.05 0.0709
+14 bp/+14 bp 4 (5.0) 5 (6.3) 0.9791 1.02 0.26–4.20 0.9791
Abbreviations: N, number of subjects; OR, odds ratio; CI, confidence interval; HLA-G, human leukocyte antigen-G; bp, base pair; 214 bp, absence of HLA-G 39UTR 14-bp
sequence; +14 bp, presence of HLA-G 39UTR 14-bp sequence.
Data are shown as numbers of cases and percentages.
1The P-values were calculated using chi-square tests.
2The P-values were from binary logistic regression analyses.
doi:10.1371/journal.pone.0098284.t001
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sHLA-G 117.2 (1st to 3rd quartiles = 45.9–179.2) U/mL and 10.1
(1st to 3rd quartiles = 6.3–26.4) U/mL, respectively; P,0.001).
All breast cancer stage groups had statistically higher sHLA-G
values than the control group and all P-values were ,0.001. In
addition, the median sHLA-G level of stage IV was significantly
higher than that of all other groups (187.2 U/mL for metastasis
and 30.7 U/mL for non-metastasis; P,0.001).
4. Diagnostic performance of serum sHLA-G for breast
cancer
Figure 2A illustrates the ROC curves of sHLA-G, CA15-3, and
CEA for discriminating patients with breast cancer (n = 80) from
the control group (n= 80). There were significant differences
among the AU-ROCs of sHLA-G, CA15-3, and CEA (P,0.001;
sHLA-G vs. CA15-3, P,0.001; sHLA-G vs. CEA, P=0.001;
CA15-3 vs. CEA, P=0.0106). When the best cut-off was
determined by the maximized sum of sensitivity and specificity,
the cut-off values to differentiate the breast cancer group from the
control group were 19.4 U/mL. The AU-ROC of sHLA-G for
detecting metastasis (stage IV) of breast cancer from all other
breast cancer groups was 0.79 (95% CI= 0.68–0.90, P,0.001)
(Figure 2B), and the sum of sensitivity and specificity in this case
was maximal with a cut-off sHLA-G level of 146.7 U/mL. The
AU-ROCs, sensitivities, and specificities of sHLA-G, CA15-3, and
CEA are summarized in Table 3. In addition, the AU-ROC of
sHLA-G for discriminating ductal carcinoma in situ (stage 0) from
healthy individuals was 0.84 (95% CI=0.74–0.94, P,0.001). We
also investigate the correlation of sHLA-G with CA15-3 and CEA.
The levels of sHLA-G did not significantly correlate with either the
CA15-3 or CEA except for the correlation between sHLA-G and
CEA (r=0.21, P=0.0075) in the total study population (Table S1).
For the correlation of sHLA-G with age, the sHLA-G showed low
positive correlations with age only in the total group according to
Spearman’s rank test. The correlation coefficients of breast cancer
group, normal controls, and total group were 0.01 (95% CI=
20.21 to 0.23, P=0.9358), 0.03 (95% CI=20.19 to 0.25,
P=0.7766), and 0.22 (95% CI= 0.07 to 0.36, P=0.0048),
respectively. According to the results of multivariate analysis
which control potential confounding factors, both age and sHLA-
G were found to be independently relevant to breast cancer
(OR=1.05, 95% CI= 1.02–1.09, P=0.003 for age; OR=1.03,
95% CI= 1.02–1.03, P,0.001 for sHLA-G). Although, slightly
affected by age, sHLA-G is still thought to have diagnostic ability
for the detection of breast cancer.
Figure 1. Serum sHLA-G concentrations in the control group and breast cancer group based on TNM stage. Levels of sHLA were
significantly increased in patients with breast cancer compared to healthy individuals (P,0.001). The median sHLA-G concentration of stage IV
patients was significantly higher than that of all other groups (P,0.001). The upper and lower ends of boxes and inner lines correspond to the upper
and lower quartiles and median values, respectively. The median values of the groups were presented on the right side of the inner lines. Whiskers
indicate minimum and maximum values, and circles denote individual values.
doi:10.1371/journal.pone.0098284.g001
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5. HLA-G expression in tissue related to
clinicopathological parameters and HLA-G genotypes
HLA-G expression was visualized by immunohistochemistry as
a brown-stained product (Figure 3). HLA-G was observed in
43.8% (32/73) of breast cancer lesions. HLA-G was expressed in
18.8% (3/16) of patients with estrogen receptor (ER)-negative
breast cancer and 50.9% (29/57) of patients with ER-positive
breast cancer. Furthermore, HLA-G expression in breast cancer
lesions was significantly associated with the homozygous presence
of 14-bp, with a P-value of 0.0407. However, HLA-G expression
was not significantly associated with other parameters, such as age
and disease stages (Table 4).
Discussion
The potential clinical relevance of HLA-G in cancer was
previously addressed in several studies [4,5]. The HLA-G system
plays a critical role in the recognition of tumor antigens and the
relevant immune responses against carcinoma. The HLA-G gene
might be responsible for the inhibition of T and NK cells,
facilitating tumor escape from immune surveillance [21,22].
Furthermore, both membrane-bound and sHLA-G isoforms
perform inhibitory functions through binding to specific receptors
of immune regulatory cells [9,10,27,28]. However, the definite
mechanism of action of HLA-G in breast cancer remains
unknown. A goal of this study was to estimate the potential role
of HLA-G in breast carcinogenesis through investigating HLA-G
polymorphisms and expression in both the tissue and serum in the
same patient population.
In terms of the clinical impact of HLA-G on cancer, the
G*01:01:02 allele, which was observed in 7.5% of the control
group and 10.0% of the breast cancer group in our study, showed
significantly increased risk for invasive cervical cancer (OR=3.52,
95% CI= 1.43–8.61, P=0.006 for homozygote) [21]. However, in
the present study, homozygotes of G*01:01:02 were not found
because of limited allelic polymorphism in the Korean population.
However, heterozygous genotypes for G*01:01:02, such as
G*01:01:01/*01:01:02 and G*01:01:02/*01:04:01, were observed
in our study, and were not strongly associated with the risk of
breast cancer. These results are similar to previously reported
Table 2. sHLA-G based on clinicopathological parameters, HLA-G expression in tissue, and the HLA-G 14-bp sequence status.
Parameters Value (n, %) sHLA-G level (U/mL) P-value1
Age ,522 (37, 46.3) 117.3 (60.6–181.0) 0.5021
$52 (43,53.8) 99.9 (37.7–178.8)
TNM stage 0 (12, 15.0) 83.6 (23.5–170.5) 0.1267
I (25, 31.3) 121.1 (40.9–177.3)
IIA (20, 25.0) 90.8 (39.3–169.2)
IIB (9, 11.3) 94.6 (49.2–118.6)
IIIA (5, 6.3) 100.3 (66.4–144.5)
IV (9, 11.3) 187.2 (155.9–198.9) 0.00493
Modified TNM stage4 I and II (54, 79.4) 103.3 (44.8–172.2) 0.0336
III and IV (14, 20.6) 165.5 (115.8–198.3)
Nuclear grade 1 (4, 6.8) 154.9 (78.6–198.4) 0.4639
2 (36, 61.0) 103.3 (43.2–161.6)
3 (19, 32.2) 79.1 (33.9–166.4)
Estrogen receptor status Negative (18, 22.5) 94.8 (30.5–201.5) 0.8627
Positive (62, 77.5) 117.8 (48.3–178.1)
Progesterone receptor status Negative (36, 45.0) 117.9 (38.2–186.2) 0.9614
Positive (44, 55.0) 117.1 (47.6–170.0)
HER2 status Negative (28, 35.0) 102.9 (46.5–134.6) 0.1929
Positive (52, 65.0) 131.4 (41.4–188.1)
HLA-G allele 214 bp 120.9 (48.3–187.2) 0.1781
+14 bp 97.2 (30.5–138.8)
HLA-G genotype 214 bp/214 bp 120.9 (48.3–187.2) 0.3922
214 bp/+14 bp 106.8 (29.6–144.7)
+14 bp/+14 bp 71.8 (30.1–134.0)
HLA-G in tissue Negative (41, 56.2) 99.9 (36.2–168.7) 0.4264
Positive (32, 43.8) 117.8 (54.4–174.7)
Abbreviations: sHLA-G, soluble human leukocyte antigen-G; HLA-G, human leukocyte antigen-G; HER2, receptor for human epidermal growth factor; bp, base pair;
214 bp, absence of HLA-G 39UTR 14-bp sequence; +14 bp, presence of HLA-G 39UTR 14-bp sequence.
Data are shown as numbers of cases and percentages or ‘median (1st to 3rd quartiles)’.
1The P-values were calculated using the Mann-Whitney U test and Kruskal-Wallis test with Bonferroni correction.
2The median age of the breast cancer group was 52.0 years.
3The median sHLA-G level of stage IV patients was significantly higher than those of other stages within the breast cancer group.
4The modified TNM stage was stratified according to Chen et al. [27]
doi:10.1371/journal.pone.0098284.t002
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results on the association between G*01:01:02 heterozygote
genotype and cervical cancer (OR=0.92, 95% CI=0.50–1.68)
[21].
The 39UTR 14-bp polymorphism was reported to be related to
the magnitude of HLA-G production by modulating HLA-G
mRNA stability [29,30]. Although the mechanisms have not been
clearly elucidated, HLA-G alleles with the presence of 14-bp
sequence (59-ATTTGTTCATGCCT-39) have been associated
with low HLA-G mRNA production [29]. HLA-G mRNA
transcripts with the presence of 14-bp could be further processed
by the removal of the first 92 bases of exon 8, yielding smaller
HLA-G transcripts known to be more stable than the complete
Figure 2. The AU-ROCs of sHLA-G, CA15-3, and CEA for predicting breast cancer. (A) The AU-ROC of sHLA-G for discriminating the breast
cancer group (n = 80) from the control group (n = 80) was 0.89 (95% CI = 0.83 to 0.94, P,0.001), and was greater than those of CA15-3 (0.54, 95%
CI = 0.45 to 0.63, P= 0.2116) and CEA (0.69, 95% CI = 0.61 to 0.78, P,0.001). (B) The AU-ROCs of sHLA-G, CA15-3, and CEA for differentiating metastasis
(n = 9) from other groups (n = 71) were 0.79 (95% CI = 0.68 to 0.90, P,0.001), 0.80 (95% CI = 0.65 to 0.95, P,0.001), and 0.67 (95% CI = 0.43 to 0.91,
P= 0.0837), respectively.
doi:10.1371/journal.pone.0098284.g002
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mRNA forms [29,30]. Regarding sHLA-G, the heterozygous and
homozygous genotypes for the presence of 14-bp (214 bp/+14 bp
and +14 bp/+14 bp) had lower sHLA-G concentrations com-
pared to the homozygote form of the absence of 14-bp (214 bp/
214 bp), both in the breast cancer group and among all subjects
including the control group. Although these observations were not
statistically significant, Chen et al. [27] documented that the
sHLA-G level was significantly lower in carriers of the +14 bp/
+14 bp genotype than in those with 214 bp/+14 bp (P=0.004)
and214 bp/214 bp genotypes (P=0.003). Thus, the influence of
the presence of HLA-G 14-bp polymorphism on sHLA-G
expression and its potential biological functions should be further
investigated and interpreted with caution.
Regarding the expression of HLA-G in breast tissue, several
studies showed that 41–66% of breast cancer lesions expressed
HLA-G [5]. In the present study, HLA-G was expressed in 43.8%
(32/73) of breast cancer tissues. In addition, He et al. [26]
demonstrated that HLA-G expression was significantly associated
with the ER status, which was concordant with our data. These
results might be related to the effects of TAM and RU486, which
function as anti-breast cancer drugs through blocking ER
receptors [31]. Furthermore, the homozygous genotype for the
presence of 14-bp was related to HLA-G expression, indicating
that HLA-G status might be involved in breast carcinogenesis.
There were several methods for the evaluation of staining,
which could affect the results of HLA-G expression in tissues. He
et al. [26] graded HLA-G expression as follows: (2) for tissue
specimens without staining, (+) for tissue specimens with less than
25% of cancer tissue and/or weakly stained, (++) for tissue
specimens with 25–50% of cancer tissue and/or moderately
stained, and (+++) for tissue specimens with.50% of cancer tissue
and/or strongly stained. Chen et al. [27] divided staining results
into four categories: negative, 1 for 1–25%, 2 for 26–50%, 3 for
51–75%, and 4 for .75%. Kruijf et al. [32] scored HLA-G in a
binary manner, considering any specific staining of tumor cells as
positive expression and no staining as no expression. We followed
the all of the three previous criteria and analyzed our data
preliminarily. However, the numbers of patients in the subdivided
groups were too small to conclude statistically significant results
with the four grade system. Therefore, we selected the binary
manner with the cut-off at 25% of staining area, which distinguish
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Figure 3. Immunohistochemistry staining of HLA-G expression
in breast cancer lesions. Positive HLA-G staining (original magnifi-
cation,6200 for A and6400 for B). Negative HLA-G staining (original
magnification,6200 for C and6400 for D).
doi:10.1371/journal.pone.0098284.g003
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between weakly and moderately stained, and found the relations
between HLA-G with breast cancer.
sHLA-G levels in the sera from patients with breast cancer and
healthy individuals were also investigated. sHLA-G concentrations
in the breast cancer group were significantly elevated compared to
those in the control group, which is similar to previously published
data. Chen et al. [27] reported that plasma sHLA-G in breast
cancer patients was significantly higher than that of control
subjects (median, 82.19 U/mL vs. 9.65 U/mL, P,0.001). In
particular, sHLA-G levels were significantly increased even in
patients with ductal carcinoma in situ (stage 0) who might have to
undergo breast-conserving surgery and radiation, in comparison to
healthy controls (P,0.001) [33]. Our findings suggest that sHLA-
G could already be up-regulated in precancerous conditions.
To date, very few studies have been published regarding the
clinical implications of sHLA-G in breast cancer in relation to
clinicopathological characteristics. Circulating sHLA-G levels are
not significantly correlated to most clinicopathological parameters,
Table 4. Association of HLA-G expression in cancer lesions with clinicopathological parameters, and HLA-G 14-bp sequence status.
Parameter Value No. of cases HLA-G expression (n) P-value1
Negative (%) Positive (%)
Age (years) ,522 35 17 (48.6) 18 (51.4) 0.2096
$52 38 24 (63.2) 14 (36.8)
TNM stage 0 12 9 (75.0) 3 (25.0) 0.2640
I 25 16 (64.0) 9 (36.0)
IIA 20 9 (45.0) 11 (55.0)
IIB 9 5 (55.6) 4 (44.4)
IIIA 5 2 (40.0) 3 (60.0)
IV 2 0 (0.0) 2 (100.0)
Modified TNM stage3 I and II 54 30 (55.6) 24 (44.4) 0.1786
III and IV 7 2 (28.6) 5 (71.4)
Nuclear grade 1 4 2 (50.0) 2 (50.0) 0.9221
2 36 19 (52.8) 17 (47.2)
3 19 11 (57.9) 8 (42.1)
Estrogen receptor status Negative 16 13 (81.3) 3 (18.8) 0.0221
Positive 57 28 (49.1) 29 (50.9)
Progesterone receptor status Negative 31 20 (64.5) 11 (35.5) 0.2166
Positive 42 21 (50.0) 21 (50.0)
HER2 status Negative 26 11 (42.3) 15 (57.7) 0.0760
Positive 47 30 (63.8) 17 (36.2)
HLA allele G*01:01:01 56 19 (33.9) 37 (66.1) 0.8504
G*01:01:02 15 5 (33.3) 10 (66.7)
G*01:01:03 7 2 (28.6) 5 (71.4)
G*01:04:01 60 16 (26.7) 44 (73.3)
214 bp 47 24 (51.1) 23 (48.9) 0.2377
+14 bp 26 17 (65.4) 9 (34.6)
HLA genotype G*01:01:01/*01:04:01 18 5 (27.8) 13 (72.2) 0.2441
G*01:04:01/*01:04:01 16 4 (25.0) 12 (75.0)
G*01:01:01/*01:01:01 14 6 (42.9) 8 (57.1)
G*01:01:01/*01:01:02 5 0 (0.0) 5 (100.0)
G*01:01:03/*01:04:01 4 0 (0.0) 4 (100.0)
G*01:01:01/*01:01:03 3 2 (66.7) 1 (33.3)
G*01:01:02/*01:04:01 4 2 (50.0) 2 (50.0)
214 bp/214 bp 47 24 (51.1) 23 (48.9) 0.1104
214 bp/+14 bp 21 12 (57.1) 9 (42.9)
+14 bp/+14 bp 5 5 (100.0) 0 (0.0) 0.0407
Abbreviations: HLA, human leukocyte antigen-G; HER2, a receptor for human epidermal growth factor; 214 bp, absence of HLA-G 39UTR 14-bp sequence; +14 bp,
presence of HLA-G 39UTR 14-bp sequence.
Data are shown as numbers of cases and percentages.
1Comparison of HLA-G expression status between each parameter using the Pearson chi-square test.
2The median age of the breast cancer group was 52.0 years.
3The modified TNM stage was stratified according to Chen et al. [27].
doi:10.1371/journal.pone.0098284.t004
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such as the age of the patients, location, TNM stage, tumor stage,
and nuclear grade, according to previous data [26,27,34].
Similarly, we also found no correlation between sHLA-G and
the clinicopathological parameters of our sample population.
However, the median sHLA-G level of stage IV patients was
significantly higher than those of patients in other stages both
within the breast cancer group (P=0.0049) and within the entire
population analyzed (P,0.001) in this study. These findings
suggest that circulating sHLA-G could have the potential to
differentiate breast cancer with metastasis from breast cancer
without metastasis, which was not previously discussed in the
literature. Furthermore, sHLA-G showed an association with
modified TNM stage, which combined stage I with II and stage III
with IV according to Chen et al. [27]. Combining these stages
increased the sample size, and therefore the power to obtain
significant P-values.
The ROC curve analyses were performed to evaluate the
feasibility of sHLA-G as a diagnostic marker for breast cancer.
Previous research showed that the AU-ROC of sHLA-G in
discriminating between breast cancer patients and healthy controls
was 0.735 (95% CI= 0.630–0.874, P,0.001) [7]. They measured
not serum sHLA-G, but plasma sHLA-G in the 120 patients with
breast cancer and 40 healthy controls. The breast cancer group
was composed of 40 invasive ductal carcinoma, 40 ductal
carcinoma in situ and 40 lobular neoplasia. In another study, the
value of AU-ROC was 0.953 (95% CI= 0.926–0.981, P,0.001)
from breast cancer patients vs. normal controls [27]. They also
determined the plasma sHLA-G in 92 primary ductal breast
cancer patients and in 70 normal controls. In our study, the AU-
ROCs for distinguishing breast cancer from control subjects was
0.89, which is intermediate between the two previous results and
was higher than those obtained for CA15-3 and CEA. The
variations of the AU-ROCs among these studies could be caused
by the differences of population set and study size. Further, there
was no information regarding the comparison of sHLA-G with
CA15-3 and CEA in breast cancer, to the best of our knowledge.
In addition, the AU-ROC of sHLA-G for discriminating ductal
carcinoma in situ from normal specimens was 0.84, showing the
prominent diagnostic utility of sHLA-G.
The AU-ROC of sHLA-G for differentiating breast cancer
metastasis from other stages of breast cancer was 0.79, which have
not been previously documented. Barrier et al. [35] evaluated the
ability of HLA-G to discriminate between metastatic and non-
metastatic cancer using immunohistochemistry in the 44 cases of
endometrial adenocarcinoma. The AU-ROC value was 0.754
(95% CI= 0.590–0.916) for metastatic vs. non-metastatic cancer
and the specificity to predict metastatic disease was 86% (95%
CI= 0.68–0.95), while the sensitivity was 63% (95% CI= 0.39–
0.87). They concluded that HLA-G may serve as a clinical marker
for the preoperative prediction of metastatic endometrial cancer.
We followed the criteria of the Barrier et al. [35] to estimate the
ability of sHLA-G for differentiating the metastatic and non-
metastatic breast cancer. Although, the AU-ROC value of CA15-3
for differentiating breast cancer metastasis from other stages of
breast cancer (0.80) was slightly higher than that of sHLA-G (0.79),
the AU-ROC of sHLA-G for discriminating the breast cancer
group from normal controls (0.89) was prominently higher than
that of CA15-3 (0.54). Thus, serum sHLA-G concentration may
potentially be a diagnostic marker for breast cancer and
metastasis.
In this study, the limited allelic polymorphism of HLA-G in the
Korean population is one of the inevitable limitations for
analyzing genotype associations. Further studies with a large
number of specimens would facilitate determining the clinical
usefulness of HLA-G polymorphism and sHLA-G as a diagnostic
marker.
Conclusions
HLA-G seems to be implicated in the immune escape
mechanisms of breast cancer. The presence of 14-bp of HLA-G
was associated with breast cancer susceptibility according to the
results of HLA-G expression in tissue. The circulating sHLA-G
levels were markedly increased in patients with breast cancer,
including ductal carcinoma in situ. In addition, the AU-ROCs of
sHLA-G for differentiating metastasis from all other groups were
high enough to determine the presence of breast cancer metastasis.
Therefore, the 14-bp HLA-G gene polymorphism could be
involved in breast carcinogenesis, and the measurement of
sHLA-G concentrations have diagnostic value for detecting breast
cancer and metastasis.
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